Penn Cancer Center Sponsors Exhibit of Cancer Patients’ Art
PHILADELPHIA-“Confronting Cancer Through Art” is a juried exhibition of inspirational artwork crafted by individuals who have been touched by cancer (see artwork). This year marks the second time that the University of Pennsylvania Cancer Center has sponsored this exhibit, which runs through October 31, 1999, at the Arthur Ross Gallery in Philadelphia. The first exhibit was presented in 1996.
PHILADELPHIAConfronting Cancer Through Art is a juried exhibition of inspirational artwork crafted by individuals who have been touched by cancer (see artwork). This year marks the second time that the University of Pennsylvania Cancer Center has sponsored this exhibit, which runs through October 31, 1999, at the Arthur Ross Gallery in Philadelphia. The first exhibit was presented in 1996.
Artmaking encourages vision, hope, and imagination, all of which foster the healing process, said Gianna Volpe, MFA, who directs the Cancer Centers Art Program and whose own artwork is part of the exhibit. The exhibit contains 65 pieces created in various media, including sculpture, quilting, painting, and photography. It can be viewed online until October 31, 1999, at the Centers website: www.oncolink.upenn.edu.
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
